Research programme: cardiovascular disease therapies - CliniGeneticsAlternative Names: Nimoxine™
Latest Information Update: 02 Feb 2011
At a glance
- Originator CliniGenetics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Atherosclerosis; Cardiovascular disorders
Most Recent Events
- 18 Sep 2007 Lead compounds are available for licensing (http://www.clinigenetics.com/main_corporate.htm)
- 08 Dec 2003 Preclinical trials in Cardiovascular disorders in France (unspecified route)
- 08 Dec 2003 Preclinical trials in Atherosclerosis in France (unspecified route)